Evidence map›Paper›PMID 33495152›Full record

ArticleAnnals of the rheumatic diseases2021

Autoantibodies targeting telomere-associated proteins in systemic sclerosis.

Brittany L Adler, Francesco Boin, Paul J Wolters, Clifton O Bingham, Ami A Shah, Carol Greider, Livia Casciola-Rosen, Antony Rosen

Open access · greenAbstract read
In one paragraph

Article in Annals of the rheumatic diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Systemic Sclerosis Association with Malignancy.Clinical reviews in allergy & immunology · 2022
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Brittany L AdlerRheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA brittany.adler@jhmi.edu.ORCID 0000-0001-9912-2435
Francesco BoinRheumatology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Paul J WoltersPulmonary, University of California, San Francisco, San Francisco, California, USA.
Clifton O BinghamRheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0002-4752-5029
Ami A ShahRheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Carol GreiderMolecular Biology and Genetics, Johns Hopkins University, Baltimore, Maryland, USA.
Livia Casciola-RosenRheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Antony RosenRheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Johns Hopkins University · USCedars-Sinai Medical Center · USUniversity of California, San Francisco · US

Funding

Sample Processing and Immunoassay Research CoreP30AR070254 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI Antony Rosen · 2016 to 2026
$8.9M
Multidisciplinary Rheumatology Training ProgramT32AR048522 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI CLIFTON O BINGHAM, LIVIA A CASCIOLA-ROSEN · 2003 to 2026
$6.4M
Phenotype-Specific Immune Responses in the Systemic VasculitidesP30AR053503 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI ROSEN, ANTONY · 2006 to 2015
$6.4M
Lung Remodeling Mediated by Telomere Dysfunction in Alveolar Type II CellsR01HL139897 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Paul j WOLTERS · 2018 to 2026
$5.5M
NHLBI NIH HHS R01 HL139897NIAMS NIH HHS P30 AR053503NIAMS NIH HHS P30 AR070254NIAMS NIH HHS T32 AR048522
6 · The paper itself

Abstract

objectivesSystemic sclerosis (SSc) is an autoimmune fibrotic disease affecting multiple tissues including the lung. A subset of patients with SSc with lung disease exhibit short telomeres in circulating lymphocytes, but the mechanisms underlying this observation are unclear.

methodsSera from the Johns Hopkins and University of California, San Francisco (UCSF) Scleroderma Centers were screened for autoantibodies targeting telomerase and the shelterin proteins using immunoprecipitation and ELISA. We determined the relationship between autoantibodies targeting the shelterin protein TERF1 and telomere length in peripheral leucocytes measured by qPCR and flow cytometry and fluorescent in situ hybridisation (Flow-FISH). We also explored clinical associations of these autoantibodies.

resultsIn a subset of patients with SSc, we identified autoantibodies targeting telomerase and the shelterin proteins that were rarely present in rheumatoid arthritis, myositis and healthy controls. TERF1 autoantibodies were present in 40/442 (9.0%) patients with SSc and were associated with severe lung disease (OR 2.4, p=0.04, Fisher's exact test) and short lymphocyte telomere length. 6/6 (100%) patients with TERF1 autoantibodies in the Hopkins cohort and 14/18 (78%) patients in the UCSF cohort had a shorter telomere length in lymphocytes or leukocytes, respectively, relative to the expected age-adjusted telomere length. TERF1 autoantibodies were present in 11/152 (7.2%) patients with idiopathic pulmonary fibrosis (IPF), a fibrotic lung disease believed to be mediated by telomere dysfunction.

conclusionsAutoantibodies targeting telomere-associated proteins in a subset of patients with SSc are associated with short lymphocyte telomere length and lung disease. The specificity of these autoantibodies for SSc and IPF suggests that telomere dysfunction may have a distinct role in the pathogenesis of SSc and pulmonary fibrosis.

Indexed as

AdultAgedAutoantibodiesAutoantigensFemaleHumansIdiopathic Pulmonary FibrosisMaleMiddle AgedScleroderma, SystemicShelterin ComplexTelomereTelomere-Binding ProteinsAutoantibodiesAutoantigensShelterin ComplexTelomere-Binding ProteinsTERF1 protein, humanautoantibodiespulmonary fibrosissclerodermasystemic

Identifiers

PMID33495152
PMCPMC8217217
OpenAlexW3125330632

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.